These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 37118323)

  • 21. Unveiling new secrets in Parkinson's disease: The glycatome.
    Chegão A; Vicente Miranda H
    Behav Brain Res; 2023 Mar; 442():114309. PubMed ID: 36706808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid Metabolism is the common pathologic mechanism between Type 2 Diabetes Mellitus and Parkinson's disease.
    Zhang X; Fan Y; Luo Y; Jin L; Li S
    Int J Med Sci; 2020; 17(12):1723-1732. PubMed ID: 32714075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts.
    Cullinane PW; de Pablo Fernandez E; König A; Outeiro TF; Jaunmuktane Z; Warner TT
    Mov Disord; 2023 Feb; 38(2):162-177. PubMed ID: 36567671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies.
    Dutta BJ; Singh S; Seksaria S; Das Gupta G; Singh A
    Pharmacol Res; 2022 Aug; 182():106358. PubMed ID: 35863719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases.
    Chung SJ; Kim MJ; Kim J; Ryu HS; Kim YJ; Kim SY; Lee JH
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1435-40. PubMed ID: 26499758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase.
    Priyadarshini M; Kamal MA; Greig NH; Reale M; Abuzenadah AM; Chaudhary AG; Damanhouri GA
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):482-9. PubMed ID: 22583431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F; Moretti A; Villa RF
    Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.
    Green H; Tsitsi P; Markaki I; Aarsland D; Svenningsson P
    CNS Drugs; 2019 Feb; 33(2):143-160. PubMed ID: 30687888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
    Hong CT; Chen KY; Wang W; Chiu JY; Wu D; Chao TY; Hu CJ; Chau KD; Bamodu OA
    Cells; 2020 Mar; 9(3):. PubMed ID: 32192190
    [No Abstract]   [Full Text] [Related]  

  • 30. A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.
    Lynn J; Park M; Ogunwale C; Acquaah-Mensah GK
    J Alzheimers Dis; 2022; 85(2):485-501. PubMed ID: 34842187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's Disease.
    Song J; Kim J
    Front Aging Neurosci; 2016; 8():65. PubMed ID: 27065205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.
    De S; Banerjee S; Rakshit P; Banerjee S; Kumar SKA
    Curr Diabetes Rev; 2024 May; ():. PubMed ID: 38747222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNAs, Parkinson's Disease, and Diabetes Mellitus.
    Wang H
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Chohan H; Senkevich K; Patel RK; Bestwick JP; Jacobs BM; Bandres Ciga S; Gan-Or Z; Noyce AJ
    Mov Disord; 2021 Jun; 36(6):1420-1429. PubMed ID: 33682937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
    Athauda D; Gulyani S; Karnati HK; Li Y; Tweedie D; Mustapic M; Chawla S; Chowdhury K; Skene SS; Greig NH; Kapogiannis D; Foltynie T
    JAMA Neurol; 2019 Apr; 76(4):420-429. PubMed ID: 30640362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review of molecular approaches that link mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
    Mani S; Sevanan M; Krishnamoorthy A; Sekar S
    Neurol Sci; 2021 Nov; 42(11):4459-4469. PubMed ID: 34480241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.
    Biosa A; Outeiro TF; Bubacco L; Bisaglia M
    Mol Neurobiol; 2018 Nov; 55(11):8754-8763. PubMed ID: 29594935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases.
    Söderbom G; Zeng BY
    Int Rev Neurobiol; 2020; 154():345-391. PubMed ID: 32739011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.